LivaNova/$LIVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LivaNova
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Ticker
$LIVN
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
2,900
ISIN
GB00BYMT0J19
Website
LivaNova Metrics
BasicAdvanced
$2.5B
-
-$4.09
0.84
-
Price and volume
Market cap
$2.5B
Beta
0.84
52-week high
$55.58
52-week low
$32.48
Average daily volume
609K
Financial strength
Current ratio
1.579
Quick ratio
1.268
Long term debt to equity
56.995
Total debt to equity
65.537
Interest coverage (TTM)
3.03%
Profitability
EBITDA (TTM)
231.773
Gross margin (TTM)
69.45%
Net profit margin (TTM)
-17.42%
Operating margin (TTM)
14.33%
Effective tax rate (TTM)
-15.01%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
4.72%
Return on equity (TTM)
-19.70%
Valuation
Price to revenue (TTM)
1.952
Price to book
2.41
Price to tangible book (TTM)
69.77
Price to free cash flow (TTM)
17.106
Free cash flow yield (TTM)
5.85%
Free cash flow per share (TTM)
267.75%
Growth
Revenue change (TTM)
7.62%
Earnings per share change (TTM)
583.36%
3-year revenue growth (CAGR)
7.45%
3-year earnings per share growth (CAGR)
27.52%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Bulls say / Bears say
LivaNova's new strategic focus on commercial execution and product innovation is expected to drive consistent revenue growth and margin improvement, with projections of approximately 14% EPS growth through 2027. (benzinga.com)
Analysts have maintained a 'Buy' rating on LivaNova, citing robust revenue and earnings growth outlooks, with price targets set at $66.00. (markets.businessinsider.com)
Institutional investors, such as Renaissance Technologies LLC, have increased their stakes in LivaNova, indicating confidence in the company's future performance. (marketbeat.com)
The unipolar patient cohort of LivaNova's RECOVER study for its VNS Therapy failed to meet its primary endpoint, leading to an 11% drop in stock value. (seekingalpha.com)
Wolfe Research downgraded LivaNova's stock from 'Outperform' to 'Peer Perform,' reflecting concerns over the company's near-term prospects. (defenseworld.net)
The Goldman Sachs Group lowered its price target for LivaNova from $64.00 to $55.00, indicating a more cautious outlook on the company's future performance. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
LivaNova News
AllArticlesVideos
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Business Wire·3 weeks ago
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Business Wire·2 months ago
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LivaNova stock?
LivaNova (LIVN) has a market cap of $2.5B as of June 27, 2025.
What is the P/E ratio for LivaNova stock?
The price to earnings (P/E) ratio for LivaNova (LIVN) stock is 0 as of June 27, 2025.
Does LivaNova stock pay dividends?
No, LivaNova (LIVN) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next LivaNova dividend payment date?
LivaNova (LIVN) stock does not pay dividends to its shareholders.
What is the beta indicator for LivaNova?
LivaNova (LIVN) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.